mRNA-4157, KEYTRUDA 25 mg/mL concentrate for solution for infusion
V940-007
Phase 3 small_molecule active
Quick answer
mRNA-4157, KEYTRUDA 25 mg/mL concentrate for solution for infusion for The participants must have a histologically confirmed diagnosis of resectable cSCC as the primary site of malignancy (metastatic skin involvement from another primary cancer or from an unknown primary cancer is not permitted). is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- The participants must have a histologically confirmed diagnosis of resectable cSCC as the primary site of malignancy (metastatic skin involvement from another primary cancer or from an unknown primary cancer is not permitted).
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active